These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38285337)

  • 1. The First Steps on AOPs' Concepts, Development, and Applications in Teratology.
    Vieira L; Souza T; Farias D
    Methods Mol Biol; 2024; 2753():151-157. PubMed ID: 38285337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semantic characterization of adverse outcome pathways.
    Wang RL
    Aquat Toxicol; 2020 May; 222():105478. PubMed ID: 32278258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse outcome pathway (AOP) development I: strategies and principles.
    Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
    Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
    Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-level overview of the OECD AOP Development Programme.
    Chauhan V; Hamada N; Wilkins R; Garnier-Laplace J; Laurier D; Beaton D; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1704-1713. PubMed ID: 35938955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways.
    Clerbaux LA; Filipovska J; Nymark P; Chauhan V; Sewald K; Alb M; Sachana M; Beronius A; Amorim MJ; Wittwehr C
    ALTEX; 2024; 41(2):233-247. PubMed ID: 37980615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse outcome pathway: a path toward better data consolidation and global co-ordination of radiation research.
    Chauhan V; Beaton D; Hamada N; Wilkins R; Burtt J; Leblanc J; Cool D; Garnier-Laplace J; Laurier D; Le Y; Yamada Y; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1694-1703. PubMed ID: 34919011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
    Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
    Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
    Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
    ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse outcome pathways: From research to regulation scientific workshop report.
    Kleinstreuer NC; Sullivan K; Allen D; Edwards S; Mendrick DL; Embry M; Matheson J; Rowlands JC; Munn S; Maull E; Casey W
    Regul Toxicol Pharmacol; 2016 Apr; 76():39-50. PubMed ID: 26774756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an adverse outcome pathway network for nephrotoxicity.
    Barnes DA; Firman JW; Belfield SJ; Cronin MTD; Vinken M; Janssen MJ; Masereeuw R
    Arch Toxicol; 2024 Mar; 98(3):929-942. PubMed ID: 38197913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
    Yamada T; Ashikaga T; Kojima H; Hirose A
    Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.
    Vinken M
    Methods Mol Biol; 2016; 1425():325-37. PubMed ID: 27311472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert consultation is vital for adverse outcome pathway development: a case example of cardiovascular effects of ionizing radiation.
    Chauhan V; Hamada N; Monceau V; Ebrahimian T; Adam N; Wilkins RC; Sebastian S; Patel ZS; Huff JL; Simonetto C; Iwasaki T; Kaiser JC; Salomaa S; Moertl S; Azimzadeh O
    Int J Radiat Biol; 2021; 97(11):1516-1525. PubMed ID: 34402738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adverse outcome pathway concept: A basis for developing regulatory decision-making tools.
    Delrue N; Sachana M; Sakuratani Y; Gourmelon A; Leinala E; Diderich R
    Altern Lab Anim; 2016 Oct; 44(5):417-429. PubMed ID: 27805824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of AOP networks for reproductive and developmental toxicity assay development.
    Knapen D; Vergauwen L; Villeneuve DL; Ankley GT
    Reprod Toxicol; 2015 Aug; 56():52-5. PubMed ID: 25889759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical hazard prediction and hypothesis testing using quantitative adverse outcome pathways.
    Perkins EJ; Gayen K; Shoemaker JE; Antczak P; Burgoon L; Falciani F; Gutsell S; Hodges G; Kienzler A; Knapen D; McBride M; Willett C; Doyle FJ; Garcia-Reyero N
    ALTEX; 2019; 36(1):91-102. PubMed ID: 30332685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A curated gene and biological system annotation of adverse outcome pathways related to human health.
    Saarimäki LA; Fratello M; Pavel A; Korpilähde S; Leppänen J; Serra A; Greco D
    Sci Data; 2023 Jun; 10(1):409. PubMed ID: 37355733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies.
    Sakuratani Y; Horie M; Leinala E
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():20-28. PubMed ID: 29316278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.